We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
Read MoreHide Full Article
AMAG Pharmaceuticals, Inc. witnessed loss of 40 cents per share in the second quarter of 2017 compared with loss of 2 cents in the year-ago quarter. The reported figure is narrower than the Zacks Consensus Estimate of a loss of 58 cents.
The company’s quarterly revenues came in at $158.4 million, up approximately 24.3% from the year-ago quarter figure of $127.4 million. The upside was driven by impressive growth in net sales of Makena. In fact, the top line slightly beat the Zacks Consensus Estimate of $158 million.
Notably, AMAG’s share price has decreased 45.8% year to date against the Zacks classified industry’s gain of 9.4%.
Quarter in Detail
Makena sales came in at $102.7 million, up 31% year over year. Combined sales of Feraheme and MuGard amounted to $27.7 million, up 12.6%. During the quarter, service revenues from CBR came in at $28 million, 14.8% higher than $24.4 million in the year-ago quarter.
Total adjusted costs and expenses increased almost 61.8% to $109.7 million (excluding one-time and special items).
Key Developments
In the reported quarter, the company launched Intrarosa, the first and only FDA-approved local non-estrogen product, for the treatment of moderate-to-severe dyspareunia (pain during intercourse), which is a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
The FDA also accepted the supplemental NDA (sNDA) of Makena subcutaneous auto-injector for review and set an action date of Feb 14, 2018.
Meanwhile, has completed the submission of a supplemental new drug application (sNDA) to the FDA for expanding Feraheme’s label, to include adult iron deficiency anemia (IDA) patients who are intolerable to oral iron treatment.
2017 Outlook
AMAG reiterated its guidance for 2017. Total revenue is expected to be in the range of $625 million-$685 million.
The company still expects revenues to in the band of $410 million-$440 million for Makena, $100 million-$110 million for Feraheme and MuGard and $110 million-$120 million for the CBR Segment.
AMAG Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Exelixis’ pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 543.59%. The share price of the company has increased 72.4% year to date.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 60.9% year to date.
Sanofi’s earnings per share estimates increased from $3.18 to $3.38 for 2017 and from $3.30 to $3.38 for 2018, over last 30 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 17.9% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
AMAG Pharmaceuticals, Inc. witnessed loss of 40 cents per share in the second quarter of 2017 compared with loss of 2 cents in the year-ago quarter. The reported figure is narrower than the Zacks Consensus Estimate of a loss of 58 cents.
The company’s quarterly revenues came in at $158.4 million, up approximately 24.3% from the year-ago quarter figure of $127.4 million. The upside was driven by impressive growth in net sales of Makena. In fact, the top line slightly beat the Zacks Consensus Estimate of $158 million.
Notably, AMAG’s share price has decreased 45.8% year to date against the Zacks classified industry’s gain of 9.4%.
Quarter in Detail
Makena sales came in at $102.7 million, up 31% year over year. Combined sales of Feraheme and MuGard amounted to $27.7 million, up 12.6%. During the quarter, service revenues from CBR came in at $28 million, 14.8% higher than $24.4 million in the year-ago quarter.
Total adjusted costs and expenses increased almost 61.8% to $109.7 million (excluding one-time and special items).
Key Developments
In the reported quarter, the company launched Intrarosa, the first and only FDA-approved local non-estrogen product, for the treatment of moderate-to-severe dyspareunia (pain during intercourse), which is a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
The FDA also accepted the supplemental NDA (sNDA) of Makena subcutaneous auto-injector for review and set an action date of Feb 14, 2018.
Meanwhile, has completed the submission of a supplemental new drug application (sNDA) to the FDA for expanding Feraheme’s label, to include adult iron deficiency anemia (IDA) patients who are intolerable to oral iron treatment.
2017 Outlook
AMAG reiterated its guidance for 2017. Total revenue is expected to be in the range of $625 million-$685 million.
The company still expects revenues to in the band of $410 million-$440 million for Makena, $100 million-$110 million for Feraheme and MuGard and $110 million-$120 million for the CBR Segment.
AMAG Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
AMAG Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | AMAG Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
AMAG currently carries a Zacks Rank #3 (Hold). Better-ranked pharma stocks in the same space include Exelixis, Inc. (EXEL - Free Report) , Enzo Biochem, Inc. (ENZ - Free Report) and Sanofi (SNY - Free Report) carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exelixis’ pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 543.59%. The share price of the company has increased 72.4% year to date.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 60.9% year to date.
Sanofi’s earnings per share estimates increased from $3.18 to $3.38 for 2017 and from $3.30 to $3.38 for 2018, over last 30 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 17.9% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>